For example, enzymes involved in the amplification and analysis of RNA can be affected by blood compo-27 nents that copurify with miRNA. Thus, if miRNAs are to be effectively utilized as biomarkers, it is important 28 to establish standardized protocols for blood collection and miRNA analysis to ensure accurate quantitation.
based on Taq-polymerase has led to numerous studies that have identified changes in the abundance of cir- 23 culating cell-free miRNA species that correlate with pathology or other events. The growing interest in devel- 24 oping miRNAs as blood biomarkers necessitates the careful consideration of the unique properties of such 25 body fluids that can make the reproducible and quantitative assessment of RNA abundance challenging. 26 For example, enzymes involved in the amplification and analysis of RNA can be affected by blood compo- 27 nents that copurify with miRNA. Thus, if miRNAs are to be effectively utilized as biomarkers, it is important 28 to establish standardized protocols for blood collection and miRNA analysis to ensure accurate quantitation. 29 Here we outline several considerations, including the type of collection tube used in sampling, the influence 30 of added anticoagulants and stabilizers, sample processing, enrichment of vesicular and other miRNA spe- 31 cies, RNA extraction approaches and enzyme selection, that affect quantitation of miRNA isolated from 32 plasma and should be considered in order to achieve reproducible, sensitive and accurate quantitation. MicroRNAs (miRNAs) are non-coding RNA molecules of 19-22 38 nucleotides that are deregulated in cancer [1, 2] neurodegeneration 39 [3], and are temporally over-or underrepresented in physiological 40 conditions including pregnancy [4] , aging [5] , and longevity [6] . Cell 41 free miRNAs that circulate in blood serum and other body fluids have 42 emerged as promising markers of disease and physiological pro- 43 cesses [1, [7] [8] [9] [10] . The validation of circulating miRNAs as biomarkers 44 requires methods to accurately identify and quantify miRNAs in 45 complex samples collected from patients. The present protocol pro- 46 vides a standard operating procedure for collection and analysis of 47 blood-derived miRNAs. This protocol was developed based on rigor- 48 ous testing of the effects of variables on the accuracy and sensitivity 49 of circulating miRNA quantitation, including vacutainer choice, plas-50 ma/serum preparation/fractionation, plasma quality control, RNA 51 extraction, and the use of a Taq polymerase mix resistant to endog- 52 enous inhibitors of polymerases of plasma [11, 12] . 53 
Quantitative RT-PCR

54
A common method used to quantify miRNAs is quantitative re- 55 verse-transcriptase polymerase chain reaction (qRT-PCR) [13] . 56 qRT-PCR is a preferred approach for the identification and quanti- 57 tation of blood biomarkers, because alternative approaches includ- 58 ing array platforms do not yet match the sensitivity of PCR-based 59 approaches [14] . Using a qRT-PCR approach, changes in plasma 60 and serum miRNA profiles have been reported to reflect various 61 physiological and pathological conditions, including diagnostic 62 and prognostic value for colorectal cancer, breast cancer, gastric 63 cancer, leukemia, lung cancer, lymphoma, oral cancer, ovarian can- 64 cer, pancreatic cancer, prostate cancer (reviewed in [1, [7] [8] [9] [10] ) and 65 other diseases or conditions [15] [16] [17] [18] . The rising interest in quanti-66 fying cell-free circulating miRNA for diagnostic and prognostic pur-67 poses requires assurance that the measured concentration 68 accurately represents the actual amounts in the samples. A major 69 consideration in the processing of RNA from plasma for analysis 70 by qRT-PCR is the sufficient removal of endogenous inhibitors of 71 polymerases, which include hemoglobin [19] , lactoferrin [20] , 72 immunoglobulin G [21] , and calcium [22] , which can co-purify 73 with nucleic acids [23] [19] , as well as interpretation of results [27, 31] . Quantitation of 127 hemolysis visually [27] , and by spectroscopy [31, 32] Fig. 1 . Plasma collection and processing for miRNA quantitation. For retrospective studies, plasma collected into citrate or EDTA, or blood collected in the absence of anti-coagulants (serum) provide acceptable data. The use of heparin as an anticoagulant strongly interferes with miRNA quantitation. This inhibition can be partially overcome by treating the samples with heparinase. For prospective studies, collection into KOx/NaF provides high reproducibility and sensitivity in miRNA quantitation [11] . Plasma/serum cleared of most cells by centrifugation at 300g are analyzed for signs of hemolysis [27, 31, 32] , and should be interpreted with caution or eliminated from the study if excessive hemolysis is present. To remove all cells and most cell debris from plasma, samples should be filtered. The choice of cut-off sizes determines which of the known miRNA-containing plasma complexes are included in the quantitation. For some collections, especially heparin-containing plasma, the best volume for purification and quantitation should be evaluated to identify the highest miRNA: interfering contaminant ratio in the RNA preparation. A spiked RNA is added during TRIzol extraction to assess yield and amplification efficiency for each RNA preparation. An additional phenol/chloroform extraction and differential silica-absorption can increase purity and quantitation efficiency several-fold. Spectroscopy is used to quantify RNA yield and purity. Single-assay, or previously validated multiplex RT analyses using looped-primers specifically designed to 3 0 ends of mature miRNAs are used for cDNA production. Quantitative PCR with the addition of Hemo KlenTaq, which is much less sensitive to blood-borne inhibitors of Taq polymerase, provides high sensitivity in miRNA quantitation. MiRNAs to evaluate for quality control and yield include miR-16, miR-451 and spiked RNA. Assay-specific normalizing miRNAs or other RNAs should be quantified along with the miRNAs of interest.
⁄ If cell pellet present in frozen plasma/serum, physically separate cell free portion from cell pellet before thaw by cutting cores. Italizised steps: not recommended if alternatives exist. Grey steps: Should be empirically validated for benefits in each study.
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consider that particles and vesicles change in the blood which in-151 cludes the loss of surface antigens for enrichment [42] Extraction and purification of miRNAs from plasma must be suf-174 ficient to remove endogenous inhibitors of polymerases, [19] [20] [21] [22] to the cDNA produced by RT for each miRNA measured [56] 
